iRhythm Technologies Azioni (NASDAQ: IRTC)

Ultime notizie per iRhythm Technologies (NASDAQ:IRTC) Azioni

iRhythm Technologies

iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.

iRhythm Technologies, Inc. - Common Stock

iRhythm Technologies Inc

<ul>
<li>Regulatory milestone enables commercial expansion into high-need international market</li>
<li>10-minute test detects early signs of kidney damage using a simple urine sample</li>
<li>Addresses global public health burden of Chronic Kidney Disease (CKD), with high relevance in the UAE &nbsp;</li>
</ul>
IRVINE, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>), a global provider of advanced diagnostic solutions, announced that its Fortel&#xAE; Kidney Disease (Microalbumin) Test has been approved for sale by the United Arab Emirates (UAE) Ministry of Health and Prevention. This key regulatory milestone enables Biomerica to offer its innovative test across the UAE, a region facing a high burden of chronic kidney disease (CKD).
The Fortel&#xAE; Kidney Disease Test is a rapid, easy-to-use diagnostic tool that provides accurate results in 10 minutes using a urine sample. By detecting low levels of microalbumin in urine (a critical early marker), the test can enable the early detection of kidney disease. Individuals with diabetes, hypertension, obesity and those over the age of 65 are at significantly increased risk for developing chronic kidney disease (CKD) and should be tested frequently. CKD is a worldwide public health problem that is highly underrecognized and more than 80% of at-risk patients are not diagnosed. Kidney disease enhances the risk of major non-communicable diseases including ischemic heart disease, stroke, cancer, etc. By 2040, CKD is projected to be the 5th highest cause of years of life lost globally.
Early detection of CKD allows for timely intervention that can slow or prevent progression to end-stage renal disease, requiring dialysis or kidney transplantation. In addition to reducing morbidity and mortality, early diagnosis can also lower the substantial economic burden associated with disease progression.

News

BMRA

UAE Ministry of Health and Prevention Approves Biomerica's Fortel Kidney Disease Test For Sale

SLNH

Soluna Signs Term Sheet For Power For Project Ellen Data Center

Piper Sandler analyst Kashy Harrison maintains Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) with a Neutral and lowers the price target from $65 to $47.

Price Target

Analyst Ratings

ENPH

Piper Sandler Maintains Neutral on Enphase Energy, Lowers Price Target to $47

Jones Trading analyst Jason Weaver maintains Angel Oak Mortgage REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOMR#NYSE">AOMR</a>) with a Buy and lowers the price target from $12.5 to $10.5.

AOMR

Jones Trading Maintains Buy on Angel Oak Mortgage REIT, Lowers Price Target to $10.5

Piper Sandler analyst Michael Lavery maintains Boston Beer Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAM#NYSE">SAM</a>) with a Neutral and lowers the price target from $240 to $230.

Piper Sandler Maintains Neutral on Boston Beer Co, Lowers Price Target to $230

Earnings

KIDZ

Classover 2024 Total Revenue $3.7M, up 19% YoY, Net Loss $(843K) vs $(433K) YoY

Broad Market Declines 2.25% as GLD rises after Alert From TradePulse
<figure class="wp-block-image size-large is-resized"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/16203552/Screenshot-2025-04-16-at-4.35.29%E2%80%AFPM-1024x786.png" alt="" class="wp-image-10860" style="width:920px;height:auto" /></figure>
SPDR Gold Trust (GLD) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 10:09 AM on April 16th, a significant trading signal occurred for SPDR Gold Trust (GLD) as it demonstrated a Power Inflow at a price of $305.32. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in GLD&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in GLD&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for GLD, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts. 
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like <a href="https://tradepulse.net/?utm_source=benzinga&amp;utm_medium=article&amp;utm_campaign=brand_awareness_apr2025">https://tradepulse.net/?utm_source=benzinga&amp;utm_medium=article&amp;utm_campaign=brand_awareness_apr2025</a>, which are responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
After Market Close UPDATE:
The price at the time of the Power Inflow was $305.32. The returns on the High price ($308.06) and Close price ($307.47) after the Power Inflow are respectively 0.9% and 0.7%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite.
Results are not indicative of future results

WIIM

Technicals

Commodities

Opinion

Signals

Markets

Trading Ideas

ETFs

SPDR Gold Shares Up ~1% After Key Signal

Elon Musk's SpaceX and Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) could play a crucial role in building U.S. President Donald Trump's Golden Dome missile defense system.
What Happened: In a report published by Reuters on Thursday, the news agency cites six people who are familiar with the matter saying the bid by Musk's SpaceX, Palantir, as well as drone manufacturing startup Anduril, emerged as ‘frontrunners' for the project.
However, the report also suggests that despite the ‘positive signals' to SpaceX, the decision process was still at a nascent stage. The companies met with officials in the Trump administration in the past few weeks to discuss the bid.
In the meetings, the companies have shared their plans for building anywhere between 400 to 1000 satellites, which will track global missile movements. There would also be a separate fleet of 200 ‘attack' satellites, the report said.
Sources cited in the report also suggest that SpaceX has offered its role in the operations as a subscription service, rather than the government owning the technology outright, though officials remain skeptical about the same.
According to the report, SpaceX is eyeing the ‘custody layer' of the operation, which involves satellites tracking missiles. Sources say SpaceX suggests it could cost anywhere between $6 billion to $10 billion to develop these satellites.
Musk's team isn't the only party involved, as there are many players eyeing up the contract. Officials in the report suggest the Pentagon has received interest from over 180 companies. The likes of Boeing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>), RTX Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>), Lockheed Martin Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>), and more are also expected to be a part of the process. Some experts anticipate that the system could cost hundreds of billions of dollars. 
Why It Matters: The news comes in as Palantir has experienced a surge in value after the company <a href="https://www.benzinga.com/government/regulations/25/04/44792590/palantir-stock-jumps-9-after-nato-adopts-ai-system-for-military-ops">successfully closed a deal</a> with the North Atlantic Treaty Organization (NATO) for its AI-driven software, which finds applications in key military operations.
Elsewhere, Musk's SpaceX continues to lead the private space exploration sector after it completed the Falcon 9 rocket's <a href="https://www.benzinga.com/general/space/25/04/44806935/spacex-launches-27th-falcon-9-rocket-from-florida-adds-27-starlink-satellites-to-orbit">27th launch and landing </a>operation from Florida's Cape Canaveral Space Force Station. Musk&#8217;s company has received <a href="https://www.benzinga.com/25/04/44655959/elon-musks-spacex-jeff-bezos-blue-origin-and-boeing-lockheeds-ula-bag-13-5-billion-pentagon-launch-contracts">over $5.9 billion worth</a> of contracts from the U.S. Space Force
The company also deployed 27 additional Starlink satellites to its constellation, bringing the total number of low Earth orbit satellites to well over 7,000. Starlink is now available in over 100 countries across the globe.
However, Musk's DOGE finds itself amid <a href="https://www.benzinga.com/25/04/44859945/whistleblower-alleges-doge-involved-in-major-cybersecurity-breach-at-us-labor-agency">a new controversy </a>as a whistleblower alleges that the department was given wide-ranging access to the sensitive data of the U.S. government's National Labor Relations Board (NLRB).
Price Action: PLTR is currently trading for $92.71 on the NASDAQ, having experienced a 23.30% YTD increase in value, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44859234/vladimir-putin-hails-elon-musk-comparing-him-to-soviet-space-program-pioneer-such-people-rarely-appear-in-the-human-population">Vladimir Putin Hails Elon Musk, Compares Him To Soviet Space Program Pioneer: &#8216;Such People Rarely Appear In The Human Population&#8217;</a></li>
</ul>
Image Via Shutterstock

SPACE

Contracts

Politics

Tech

PLTR

TSLA

SpaceX, Palantir 'Frontrunners' In Bid To Build Donald Trump's Golden Dome: Report

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 150 points on Thursday.
Shares of Alcoa Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AA#NYSE">AA</a>) fell sharply in today's pre-market trading following <a href="https://www.benzinga.com/news/earnings/25/04/44853254/alcoa-shares-gain-after-mixed-q1-results-eps-beat-revenues-miss">first-quarter results</a>.
Alcoa reported quarterly earnings of $2.15 per share, which beat the analyst consensus estimate of $1.70. Quarterly revenue came in at $3.37 billion, which missed the analyst consensus estimate of $3.53 billion and is an increase over revenue of $2.6 billion from the same period last year.
Alcoa shares dipped 2.6% to $24.43 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Sionna Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SION#NASDAQ">SION</a>) shares tumbled 30% to $7.00 in pre-market trading following a 5% gain on Wednesday.</li>
<li>Mercer International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MERC#NASDAQ">MERC</a>) shares dipped 20.4% to $4.10 in pre-market trading. Mercer International will release its first quarter results for the period ending March 31, 2025 on Thursday, May 1, after the closing bell.</li>
<li>InnovAge Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) fell 15.5% to $2.40 in pre-market trading.</li>
<li>Torrid Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) fell 14.4% to $5.01 in pre-market trading after gaining around 6% on Wednesday.</li>
<li>Liberty Latin America Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LILAK#NASDAQ">LILAK</a>) dipped 11.4% to $4.61 in pre-market trading.</li>
<li>Interface, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TILE#NASDAQ">TILE</a>) shares fell 8.7% to $17.01 in pre-market trading.</li>
<li>QXO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NASDAQ">QXO</a>) fell 7.4% to $13.20 in pre-market trading as the company announced the pricing of common stock offering.</li>
<li>TransAlta Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAC#NYSE">TAC</a>) fell 6.3% to $8.12 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/04/44836659/top-3-industrials-stocks-that-may-plunge-this-month">Top 3 Industrials Stocks That May Plunge This Month</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Movers

CURV

INNV

LILAK

MERC

SION

TILE

Alcoa Posts Weak Revenue, Joins QXO And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Piper Sandler analyst Michael Lavery maintains Celsius Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) with a Overweight and raises the price target from $43 to $44.

CELH

Piper Sandler Maintains Overweight on Celsius Holdings, Raises Price Target to $44

Macro Economic Events

Global

Economics

ECB Cuts Refi Rate From 2.65% To 2.4%, Cuts Deposit Facility Rate From 2.5% To 2.25%

European certification for PD-L1 IHC 22C3 pharmDx to help gastric or GEJ adenocarcinoma patients for KEYTRUDA&#xAE; therapy
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.agilent.com&amp;esheet=54239505&amp;newsitemid=20250417981526&amp;lan=en-US&amp;anchor=Agilent+Technologies+Inc.&amp;index=1&amp;md5=189415f0603bad84f35737c63c76e8f5">Agilent Technologies Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) today announced its <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.agilent.com%2Fen-us%2Fproduct%2Fpharmdx%2Fpd-l1-ihc-22c3-pharmdx%2Fpd-l1-ihc-22c3-pharmdx-product-page&amp;esheet=54239505&amp;newsitemid=20250417981526&amp;lan=en-US&amp;anchor=PD-L1+IHC+22C3+pharmDx&amp;index=2&amp;md5=21cf51e6b3279e302118ed584b1c2264">PD-L1 IHC 22C3 pharmDx</a> (Code SK006) assay has received European IVDR certification for the use as a Companion Diagnostic (CDx) to aid in the identification of gastric or gastroesophageal Junction (GEJ) adenocarcinoma patients who may be eligible for treatment with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.keytrudahcp.com%2F&amp;esheet=54239505&amp;newsitemid=20250417981526&amp;lan=en-US&amp;anchor=KEYTRUDA%26%23174%3B&amp;index=3&amp;md5=0c3043ee2dca3cb48ea79aaa891d2630">KEYTRUDA&#xAE;</a> (pembrolizumab)1. PD-L1 IHC 22C3 pharmDx (Code SK006) is approved for exclusive use with the Agilent Autostainer Link 48 advanced staining solution. KEYTRUDA is an anti-PD-1 therapy developed by <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.merck.com%2F&amp;esheet=54239505&amp;newsitemid=20250417981526&amp;lan=en-US&amp;anchor=Merck&amp;index=4&amp;md5=d752f5b3ee034d4f80798653f8ac39a7">Merck</a> (known as MSD outside the United States and Canada).
In addition to gastric or GEJ adenocarcinoma, PD-L1 IHC 22C3 pharmDx is IVDR certified as an aid in identifying non-small cell lung cancer (NSCLC), urothelial carcinoma, esophageal cancer, head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), and cervical cancer patients for treatment with KEYTRUDA. Consequently, PD-L1 IHC 22C3 pharmDx is labeled for seven cancer indications and is the only IVDR-certified CDx to identify gastric and GEJ adenocarcinoma patients for treatment with KEYTRUDA.

Agilent Technologies Gets European Certification For PD-L1 IHC 22C3 pharmDx To Help Gastric Or GEJ Adenocarcinoma Patients for KEYTRUDA Therapy

U.S. President Donald Trump on Thursday lashed out at Federal Reserve Chair Jerome Powell on Tuesday, calling him "Too Late and Wrong" over the central bank's ongoing reluctance to cut interest rates, just as market forecasts increasingly price in a <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44850021/fed-chair-powell-says-crypto-and-banking-rules-will-loosen-as-sector-matures">prolonged Fed pause.</a>
What Happened: "The ECB is expected to cut interest rates for the 7th time," Trump <a href="https://truthsocial.com/@realDonaldTrump/posts/114352766082542122">posted </a>on social media. "And yet, ‘Too Late' Jerome Powell of the Fed, who is always TOO LATE AND WRONG, yesterday issued a report which was another, and typical, complete ‘mess!'"
Trump's tirade comes at a time when U.S. market participants, as tracked by Polymarket, are overwhelmingly betting on no change in the Fed's policy stance for its upcoming May 7 meeting. 
According to Polymarket odds, the <a href="https://polymarket.com/event/fed-decision-in-may-2025?tid=1744886504787">probability</a> of no change in rates sits at a commanding 88%, while just 10% expect a 25 basis point cut and only 2% foresee a more aggressive 50+ basis point reduction.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44849027/russia-reportedly-looking-into-creating-its-own-stablecoin">Russia Reportedly Looking Into Creating Its Own Stablecoin</a>
These expectations reflect widespread skepticism that Powell will move swiftly enough to ease financial conditions, despite signs of moderating inflation and Trump's claim that "oil prices are down, groceries (even eggs!) are down." 
Polymarket's data points to this belief, suggesting the Fed may stay on hold until at least the summer.
The president added that "the USA is getting RICH ON TARIFFS," and argued Powell "should have lowered interest rates, like the ECB, long ago." 
He concluded the post with a sharp warning: "Powell's termination cannot come fast enough!"
Why It Matters: This isn't Trump's first attack on the central banker he himself appointed in 2018.
But the criticism lands at a sensitive time, as markets navigate policy uncertainty, global trade tension, and a volatile macroeconomic backdrop.
According to Polymarket <a href="https://polymarket.com/event/will-trump-remove-jerome-powell">odds</a> as of Apr. 17, there's an 18% chance that Trump will remove Powell from his role by the end of 2025, a slight dip from earlier in the week but still notable amid growing political pressure.
The Fed's recent report, which Trump labeled a "complete mess," has not been detailed publicly, but the criticism underscores a long-standing rift between Trump and Powell, whom Trump appointed in 2018 but later frequently criticized during his presidency for not aligning monetary policy with his economic goals.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44845787/as-us-economy-resembles-emerging-market-bitcoin-is-more-mag-8-than-gold-mike-novogratz-says">As US Economy Resembles &#8216;Emerging Market&#8217;, Bitcoin Is More &#8216;MAG-8&#8217; Than Gold, Mike Novogratz Says</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Donald Trump Blasts 'Too Late And Wrong' Fed Chair Powell, But Polymarket Traders Doubt His 'Termination' Will Come 'Fast Enough'

ACNT

Ascent Industries Signs Contract Expected To Generate Over $750K In Additional Annual EBITDA

Guidance

Utz Sees Q1 2025 Net Sales Growth 1.5%-1.7% YoY; Sees Adj. EPS $0.14-$0.16 Vs $0.14 Estimate

CLDI

Calidi Biotherapeutics Receives FDA Clearance Of IND Application For CLD-201 In Solid Tumors

SYDNEY, April 17, 2025 (GLOBE NEWSWIRE) -- Tilray Medical ("Tilray"), a division of Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>, TSX:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#TSX">TLRY</a>), a global company in medicinal cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, has announced the availability of its medical cannabis edibles, Good Supply Pastilles, to patients in Australia. This launch marks Tilray Medical's first medical cannabis edible offering in the country, providing patients with a sugar-free and vegan-friendly treatment option.
Denise Faltischek, Chief Strategy Officer and Head of International, Tilray Brands, stated, "Our dedication to innovation and patient care drives us to continuously expand our offerings, ensuring that patients receive the best possible treatment options tailored to meet their needs and preferences. The expansion of our medical cannabis portfolio with the introduction of Good Supply Pastilles in Australia is a significant milestone for Tilray Medical. We are committed to providing high-quality, accessible medical cannabis products in convenient formats to patients worldwide."
Good Supply Pastilles are available in the following options:
<ul>
<li>Good Supply Pastilles THC10 (Strawberry)</li>
<li>Good Supply Pastilles THC10 CBD10 (Pineapple)</li>
<li>Good Supply Pastilles CBD20 (Raspberry) &nbsp;</li>
</ul>
Medical cannabis patients are now able to purchase the Good Supply Pastilles in packs of 60 from Tilray Direct or their local medical cannabis distributors.
Tilray continues to be a leading provider of EU-GMP certified medical cannabis to patients, physicians, pharmacies, hospitals, governments, and researchers globally. Today, Tilray offers a comprehensive portfolio of THC and CBD products in over 20 countries, supporting medical trials worldwide to study the efficacy of medical cannabis for various conditions.

TLRY

TSX:TLRY

Tilray Medical Announces Availability Of Medical Cannabis Edibles, Good Supply Pastilles, To Patients In Australia

<h3>Gainers</h3>
<ul>
<li>Unifi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UFI#NYSE">UFI</a>) stock moved upwards by 22.3% to $5.65 during Thursday's pre-market session. The company's market cap stands at $103.6 million. </li>
<li>Damon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMN#NASDAQ">DMN</a>) stock rose 16.12% to $0.0. The company's market cap stands at $2.8 million. </li>
<li>Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) shares moved upwards by 13.63% to $0.14. The company's market cap stands at $6.8 million. </li>
<li>QVC Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QVCGA#NASDAQ">QVCGA</a>) stock rose 12.94% to $0.16. The market value of their outstanding shares is at $66.5 million. </li>
<li>Birks Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BGI#AMEX">BGI</a>) shares rose 9.54% to $0.97. The company's market cap stands at $18.6 million. </li>
<li>Greenlane Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) stock moved upwards by 8.42% to $0.26. The market value of their outstanding shares is at $2.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Culp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CULP#NYSE">CULP</a>) shares fell 18.0% to $3.0 during Thursday's pre-market session. The company's market cap stands at $37.6 million. </li>
<li>Twin Vee PowerCats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEE#NASDAQ">VEEE</a>) shares decreased by 13.13% to $2.3. The market value of their outstanding shares is at $3.4 million. </li>
<li>Nerdy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRDY#NYSE">NRDY</a>) stock declined by 8.97% to $1.32. The market value of their outstanding shares is at $156.7 million. </li>
<li>Top Win International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOPW#NASDAQ">TOPW</a>) stock decreased by 8.37% to $2.41. The company's market cap stands at $59.9 million. </li>
<li>Ballys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALY#NYSE">BALY</a>) stock decreased by 7.69% to $15.01. The market value of their outstanding shares is at $728.1 million. </li>
<li>Color Star Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADD#NASDAQ">ADD</a>) stock decreased by 6.49% to $0.75. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BALY

CULP

GNLN

NRDY

QVCGA

TOPW

VEEE

12 Consumer Discretionary Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Channel Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#AMEX">CHRO</a>) stock increased by 86.5% to $2.34 during Thursday's pre-market session. The market value of their outstanding shares is at $14.1 million. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) stock rose 34.33% to $0.04. </li>
<li>InnovAge Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) stock increased by 19.71% to $3.4. The market value of their outstanding shares is at $459.8 million. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) stock increased by 19.35% to $7.16. The market value of their outstanding shares is at $147.4 million. </li>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) shares rose 14.75% to $1.4. The market value of their outstanding shares is at $5.0 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) shares rose 14.25% to $1.13. The company's market cap stands at $15.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) shares fell 36.0% to $1.26 during Thursday's pre-market session. The market value of their outstanding shares is at $39.3 million. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) shares decreased by 23.9% to $0.19. As per the news, the Q4 earnings report came out 4 days ago. </li>
<li>Sophia Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPH#NASDAQ">SOPH</a>) stock declined by 19.58% to $2.26. The company's market cap stands at $150.1 million. </li>
<li>UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) stock declined by 19.33% to $472.0. The company's market cap stands at $431.7 billion. As per the press release, Q1 earnings came out today. </li>
<li>Tourmaline Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRML#NASDAQ">TRML</a>) shares declined by 15.98% to $12.2. The company's market cap stands at $313.3 million. </li>
<li>enVVeno Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNO#NASDAQ">NVNO</a>) shares declined by 15.13% to $2.02. The company's market cap stands at $35.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CHRO

FORA

NVNO

QNRX

SBFM

SOPH

STSS

SXTC

TNFA

TRML

12 Health Care Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Urban-gro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) stock increased by 13.5% to $0.75 during Thursday's pre-market session. The market value of their outstanding shares is at $9.4 million. </li>
<li>Hertz Global Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>) shares rose 13.24% to $6.47. The company's market cap stands at $1.9 billion. </li>
<li>Elong Power Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELPW#NASDAQ">ELPW</a>) stock rose 13.23% to $3.68. The market value of their outstanding shares is at $184.2 million. </li>
<li>Ideal Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPWR#NASDAQ">IPWR</a>) shares increased by 11.55% to $5.6. The market value of their outstanding shares is at $46.6 million. </li>
<li>Cycurion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCU#NASDAQ">CYCU</a>) shares moved upwards by 10.55% to $0.46. The market value of their outstanding shares is at $5.4 million. </li>
<li>Orion Group Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORN#NYSE">ORN</a>) shares increased by 8.85% to $6.39. The company's market cap stands at $249.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lucas GC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGCL#NASDAQ">LGCL</a>) stock decreased by 12.3% to $0.33 during Thursday's pre-market session. The company's market cap stands at $26.5 million. </li>
<li>Odyssey Marine Explr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMEX#NASDAQ">OMEX</a>) shares fell 11.94% to $0.61. The company's market cap stands at $17.6 million. </li>
<li>ManpowerGroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAN#NYSE">MAN</a>) shares declined by 10.12% to $44.5. The company's market cap stands at $2.0 billion. As per the press release, Q1 earnings came out today. </li>
<li>Alta Equipment Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALTG#NYSE">ALTG</a>) stock declined by 9.41% to $3.66. The market value of their outstanding shares is at $121.4 million. </li>
<li>High-Trend International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTCO#NASDAQ">HTCO</a>) shares fell 7.83% to $1.06. The company's market cap stands at $128.1 million. </li>
<li>Professional Diversity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPDN#NASDAQ">IPDN</a>) shares decreased by 7.44% to $1.12. The company's market cap stands at $2.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALTG

CYCU

ELPW

HTCO

IPDN

IPWR

LGCL

OMEX

UGRO

12 Industrials Stocks Moving In Thursday's Pre-Market Session

Press Releases

iRhythm Technologies to Participate in the Wolfe Research 2024 Healthcare Conference

Health Care

iRhythm Data Presented at the American Heart Association 2024 Scientific Sessions Reinforce Clinical and Health Economic Value of Zio Long-Term Continuous Monitoring

iRhythm Technologies to Participate in the Citi 2024 Global Healthcare Conference

iRhythm Technologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference

iRhythm Technologies Shares Preliminary Fourth Quarter 2024 Highlights and Business Update at the 43rd Annual J.P. Morgan Healthcare Conference

iRhythm Technologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

iRhythm Technologies Announces Fourth Quarter and Full Year 2024 Financial Results

iRhythm Unveils New Real-World Data at ACC.25 Demonstrating the Benefits of  Zio® Long-Term Continuous Monitoring for Arrhythmia Detection

Turing Medical Names Transformative Med Tech Leader Kevin King as President and Chief Executive Officer

General

iRhythm Technologies Releases 2024 Corporate Sustainability Report That Demonstrates Ongoing Commitment to Culture of Quality and Sustainability

Comments

iRhythm Technologies

Notizie

Ultime notizie per iRhythm Technologies (NASDAQ:IRTC) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO